News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 5.
News about: Pharynx (naso-, oro-, hypopharynx) → cancer profile · × Clear filters
TG4050 neoantigen vaccine as adjuvant treatment in head and neck cancer: no relapses among 16 vaccinated patients in a randomised phase 1 trial
In a randomised phase 1 trial (NCT04183166), patients with completely resected head and neck squamous cell carcinoma received TG4050, an individually designed vaccine on a Modified Vaccinia Ankara viral vector encoding up to 30 predicted patient-specific neoantigens. In the arm vaccinated immediately after adjuvant therapy, none of the 16 evaluable patients relapsed at a median follow-up of 30 mon…
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer
Five-year follow-up of the phase 2/3 JCOG1008 trial (n=261) confirmed that weekly cisplatin (40 mg/m2, seven cycles) is noninferior to the 3-weekly schedule (100 mg/m2, three cycles) in postoperative chemoradiotherapy for high-risk locally advanced squamous cell carcinoma of the head and neck. At a median follow-up of 5.6 years, 5-year overall survival was 71.2% in the weekly arm versus 58.7% in t…
Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study
The phase Ib/II OrigAMI-4 study reports pivotal results for amivantamab, a bispecific EGFR-MET antibody, in patients with recurrent or metastatic head and neck squamous cell carcinoma who progressed after checkpoint inhibitor therapy and chemotherapy. This represents a heavily pretreated population with limited therapeutic options, and the study was published in the Journal of Clinical Oncology (V…
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study
The Phase III LEAP-010 trial, published in the Journal of Clinical Oncology, evaluated whether adding the multi-kinase inhibitor lenvatinib to pembrolizumab improves outcomes in patients with PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma treated in the first-line setting. The study compared pembrolizumab plus lenvatinib against pembrolizumab plus placebo, with overal…
Multi-omic characterization of nasopharyngeal carcinoma delineates the subtype-specific landscape of response to induction chemotherapy
A study published in Nature Cancer by Li et al. presents a comprehensive multi-omics analysis of nasopharyngeal carcinoma (NPC), a malignancy most prevalent in Southeast Asia and southern China. The researchers identified three distinct molecular subtypes of NPC, each characterized by unique immune microenvironment profiles and differing responses to induction chemotherapy. These findings could pa…